Apheresis therapy in immunopathologically classified multiple sclerosis patients
https://d-nb.info/1204636001/34
Conclusion
Our  results show that   the  response  to  apheresis  treatment could  be  predicted  by immunopathological  patterns  as  well  as involvement of  the  cognitive  and  brainstem systems. Potentially, IA is more effective than PLEX, but this has to be clarified in further studies.  Different  pathological  subtypes of  early  active  multiple  sclerosis  lesions  suggests different  pathophysiological  mechanism  of lesion development and thus may explain  the varying therapy  responses. Pattern  I  and  II  lesions  show sharp  lesion  edges  and an infiltration  with  T-cells  and  macrophages.  Additionally, an  antibody  and  complement-mediated  mechanism  of  demyelination  is  suggested  in  pattern  II. These  patients  also showed the most success from the apheresis treatment. In contrast, in pattern III lesions a primary  oligodendrocytic  damage  may  play  an  important  role  in  lesion  pathogenesis; patients showing this pattern are not amenable to apheresis treatments.
			
			
									
						
										
						PhD thesis about patterns and plasmapheresis
A forum to discuss research on the origins of MS and its development.
			Return to “MS Etiology and Pathogenesis”
			
				Jump to
				
			
		
			
			
	
	- Multiple Sclerosis
- ↳ General Discussion
- ↳ Introductions
- ↳ Drug Pipeline
- ↳ Regimens
- ↳ Undiagnosed
- ↳ MS Etiology and Pathogenesis
- Treatments
- ↳ Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- ↳ Low Dose Naltrexone
- ↳ Tysabri (Antegren, Natalizumab)
- ↳ Copaxone
- ↳ Glatopa
- ↳ Avonex
- ↳ Rebif
- ↳ Betaseron
- ↳ Plegridy
- ↳ Novantrone
- ↳ Aimspro
- ↳ Diet
- ↳ Stem Cells
- ↳ Antibiotics
- ↳ Campath (Lemtrada, Alemtuzumab)
- ↳ Gene Therapy
- ↳ Natural Approach
- ↳ Biotin (Qizenday, Cerenday, MD1003)
- ↳ Coimbra High-Dose Vitamin D Protocol
- ↳ Statins
- ↳ Tcelna (Tovaxin)
- ↳ Revimmune (Cyclophosphamide, Cytoxan)
- ↳ Medical Devices
- ↳ Rituxan (Rituximab)
- ↳ Ocrevus (Ocrelizumab)
- ↳ Kesimpta (Ofatumumab)
- ↳ Briumvi (Ublituximab-xiiy)
- ↳ General Medications
- ↳ Tecfidera (BG-12, Dimethyl fumarate)
- ↳ Vumerity (Diroximel fumarate)
- ↳ Bafiertam (Monomethyl fumarate)
- ↳ Gilenya
- ↳ Aubagio (Teriflunomide)
- ↳ Mayzent (Siponimod)
- ↳ Zeposia (Ozanimod)
- ↳ Ponvory (Ponesimod)
- ↳ Mavenclad (Cladribine)
- ↳ Ampyra (Dalfampridine)
- ↳ Medical Marijuana
- ↳ Sativex
- ↳ Chiropractic Treatment
- Life
- ↳ Daily Life
- ↳ Veterans and MS
- ↳ Trigeminal Neuralgia in MS
- ↳ Reading Nook
- ↳ Humor
- ↳ Shopping
- ↳ Friends and Family
- ↳ Mental & Spiritual Health
- ↳ Exercise and Physical Therapy
- ↳ Under 25 with MS
- ↳ MS in the Golden Years
- ↳ Parenting Kids With MS
- ↳ Parents with MS
- ThisIsMS.com
- ↳ Site Support
- ↳ Suggestions
